In a significant development for Alzheimer’s research, a new drug, NeuroVex, has demonstrated the ability to slow the progression of the disease in clinical trials. Developed by a team at the University of California, San Francisco, NeuroVex targets amyloid-beta plaques in the brain, which are associated with Alzheimer’s.
The Phase 3 clinical trial involved 1,200 participants with early-stage Alzheimer’s. Results showed a 30% reduction in cognitive decline over 18 months compared to a placebo. Dr. Elena Martinez, lead researcher, stated, “NeuroVex offers hope for patients by addressing the underlying pathology of Alzheimer’s, not just the symptoms.”
While the findings are promising, experts caution that further research is needed to assess long-term effects and potential side effects. The research team plans to seek FDA approval, aiming to make NeuroVex available to patients within the next two years.
